Industry
Biotechnology
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 1:01 pm
Portfolio Pulse from Benzinga Insights
June 24, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 10:22 am
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 10:47 am
Portfolio Pulse from Benzinga Insights
May 10, 2024 | 6:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 12:25 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 12:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.